OBJECTIVE: Eosinophilic oesophagitis (EoE) is a chronic inflammatory condition of the oesophagus with limited treatment options. No previous transgenic model has specifically targeted the oesophageal mucosa to induce oesophageal eosinophilia. DESIGN: We developed a mouse model that closely resembles EoE by utilising oxazolone haptenation in mice with transgenic overexpression of an eosinophil poietic and survival factor (interleukin (IL)-5) in resident squamous oesophageal epithelia. RESULTS: Overexpression of IL-5 in the healthy oesophagus was achieved in transgenic mice (L2-IL5) using the squamous epithelial promoter Epstein-Barr virus ED-L2. Oxazolone-challenged L2-IL5 mice developed dose-dependent pan-oesophageal eosinophilia, including eosinophil microabscess formation and degranulation as well as basal cell hyperplasia. Moreover, oesophagi expressed increased IL-13 and the eosinophil agonist chemokine eotaxin-1. Treatment of these mice with corticosteroids significantly reduced eosinophilia and epithelial inflammation. CONCLUSIONS: L2-IL5 mice provide a novel experimental model that can potentially be used in preclinical testing of EoE-related therapeutics and mechanistic studies identifying pathogenetic features associated with mucosal eosinophilia.
OBJECTIVE:Eosinophilic oesophagitis (EoE) is a chronic inflammatory condition of the oesophagus with limited treatment options. No previous transgenic model has specifically targeted the oesophageal mucosa to induce oesophageal eosinophilia. DESIGN: We developed a mouse model that closely resembles EoE by utilising oxazolone haptenation in mice with transgenic overexpression of an eosinophil poietic and survival factor (interleukin (IL)-5) in resident squamous oesophageal epithelia. RESULTS: Overexpression of IL-5 in the healthy oesophagus was achieved in transgenic mice (L2-IL5) using the squamous epithelial promoter Epstein-Barr virus ED-L2. Oxazolone-challenged L2-IL5mice developed dose-dependent pan-oesophageal eosinophilia, including eosinophil microabscess formation and degranulation as well as basal cell hyperplasia. Moreover, oesophagi expressed increased IL-13 and the eosinophil agonist chemokine eotaxin-1. Treatment of these mice with corticosteroids significantly reduced eosinophilia and epithelial inflammation. CONCLUSIONS:L2-IL5mice provide a novel experimental model that can potentially be used in preclinical testing of EoE-related therapeutics and mechanistic studies identifying pathogenetic features associated with mucosal eosinophilia.
Authors: J Paul Justice; Michael T Borchers; Jeffrey R Crosby; Edith M Hines; Huahao H Shen; Sergei I Ochkur; Michael P McGarry; Nancy A Lee; James J Lee Journal: Am J Physiol Lung Cell Mol Physiol Date: 2002-09-13 Impact factor: 5.464
Authors: James J Lee; Dawn Dimina; MiMi P Macias; Sergei I Ochkur; Michael P McGarry; Katie R O'Neill; Cheryl Protheroe; Ralph Pero; Thanh Nguyen; Stephania A Cormier; Elizabeth Lenkiewicz; Dana Colbert; Lisa Rinaldi; Steven J Ackerman; Charles G Irvin; Nancy A Lee Journal: Science Date: 2004-09-17 Impact factor: 47.728
Authors: Patrick Flood-Page; Andrew Menzies-Gow; Simon Phipps; Sun Ying; Arun Wangoo; Mara S Ludwig; Neil Barnes; Douglas Robinson; A Barry Kay Journal: J Clin Invest Date: 2003-10 Impact factor: 14.808
Authors: Syu-Jhe Chien; Kathleen A Silva; Victoria E Kennedy; Harm HogenEsch; John P Sundberg Journal: Exp Mol Pathol Date: 2015-08-29 Impact factor: 3.362
Authors: Kelly A Whelan; Jamie F Merves; Veronique Giroux; Koji Tanaka; Andy Guo; Prasanna M Chandramouleeswaran; Alain J Benitez; Kara Dods; Jianwen Que; Joanne C Masterson; Shahan D Fernando; Bridget C Godwin; Andres J Klein-Szanto; Kudakwashe Chikwava; Eduardo D Ruchelli; Kathryn E Hamilton; Amanda B Muir; Mei-Lun Wang; Glenn T Furuta; Gary W Falk; Jonathan M Spergel; Hiroshi Nakagawa Journal: Gut Date: 2016-02-16 Impact factor: 23.059